This is a randomized, double-blind, 2-arm, parallel group study of up to 274 evaluable patients designed to evaluate the safety and efficacy of the histone deacetylase 6 (HDAC6) inhibitor ricolinostat for painful DPN.

开始日期2020-12-07

申办/合作机构

Regenacy Pharmaceuticals LLC

100 项与 Rocilinostat 相关的临床结果

登录后查看更多信息

100 项与 Rocilinostat 相关的转化医学

登录后查看更多信息

100 项与 Rocilinostat 相关的专利（医药）

登录后查看更多信息

255

项与 Rocilinostat 相关的文献（医药）

2025-07-01·BIOORGANIC CHEMISTRY

Design and synthesis of novel Hydroxamate and non-Hydroxamate HDAC inhibitors based on Chromone and Quinazolone scaffolds

Article

作者: Ashraf, Rosaline ; Abouzid, Khaled A M ; Soror, Sameh ; Ibrahim, Esraa ; Serya, Rabah A T ; Haffez, Hesham ; Adel, Mai

The development of selective histone deacetylase (HDAC) inhibitors represents an encouraging approach for cancer therapy. In this study, we report design, synthesis, and biological evaluation of hydroxamate, amidoxime, and carboxylic acid-based derivatives as novel HDAC inhibitors. The synthesized compounds were assessed for their inhibitory activity against multiple HDAC isoforms, particularly HDAC6, 7, and 8. Compounds 13, 16, 20, and 26 exhibited potent and selective inhibition of HDAC6. Compound 26 exhibited the most potent inhibitory activity against HDAC6, with an IC₅₀ value of 70 nM. Additionally, compounds 17 and 23 demonstrated significant broad-spectrum antiproliferative activity across various cancer cell lines compared to other tested derivatives. Furthermore, compounds 17 and 23 showed promising total pan-HDAC inhibitory activity. Subsequent biological studies revealed that compounds 13, 16, 17, 20, 23, and 26 induced a combination of early and late apoptosis along with necrosis. In silico studies, including molecular docking and ADME predictions, were also conducted. Collectively, these findings highlight the potential of these compounds as promising candidates for the development of a novel class of selective HDAC6 inhibitors in the future.

2025-07-01·BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Epigenetic targeting of DNA damage response (DDR)-related mechanisms to overcome acquired cisplatin resistance of tumor cells

Article

作者: Abbey, Lena ; Sekeres, Marlena ; Lengle, Daniel ; Fischer, Fabian ; Kassack, Matthias Ulrich ; Kurz, Thomas ; Fritz, Gerhard

Mechanisms of the DNA damage response (DDR) are considered as useful targets to overcome tumor cell resistance. We investigated the impact of various classes of histone deacetylase inhibitors (HDACi) (i.e. broad-spectrum HDACi (vorinostat), class I HDACi (entinostat), preferential class IIb HDAC6i (ricolinostat) and dual HDAC class I/IIb inhibitors (HDAC1/6i)) on mechanisms of the DDR using parental (J82^WT) and cisplatin (CisPt)-resistant bladder carcinoma cells (J82^CisR). Mono-treatment with entinostat revealed relatively low genotoxic and DDR-activating potency, while showing similar antiproliferative, cytotoxic and pro-apoptotic activities as the other HDACi. Despite its low DNA double-strand break (DSB) forming potency with mono-treatment, entinostat conferred the highest synergistic cytotoxicity (CI ≤ 0.8) in J82^CisR following co-treatment with cisplatin. Notably, this effect is independent of Pt-(GpG)-DNA-intrastrand-crosslink formation. Entinostat increases the level of CisPt-induced DNA strand-breaks, promotes replication and transcription blockage, pRPA32 foci formation, PARP- and caspase-7 cleavage, influenced the activation of DDR-related factors (e.g. γH2AX, pp53, pRPA32, pKap1), reverted CisPt-induced p53 acetylation and blocked drug-stimulated mRNA expression of multiple DSB (HR, NHEJ)- and BER repair-related factors. Summarizing, the class I-selective HDACi entinostat reveals the lowest DDR-activating potency in mono-treatment and the highest anticancer efficacy in combination with CisPt, likely involving inhibition of HDAC3. This is due to amplification of replicative and transcriptional stress caused by CisPt treatment as well as interference with DDR mechanisms and DNA repair, eventually promoting apoptosis. Thus, epigenetic targeting of DDR-related death pathways by class I HDACi is useful to overcome acquired CisPt resistance of tumor cells.

2025-07-01·BIOORGANIC CHEMISTRY

Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor

Article

作者: Wan, Yichao ; Chen, Chen ; Zhong, Yidong ; Liang, Tao ; Fang, Hao ; Ma, Xiaochun ; Hou, Xuben

In stark contrast to other HDAC isoforms, deletion or inhibition of HDAC6 suppresses cell proliferation without lethality or defective phenotypes, thereby establishing HDAC6 as a compelling anti-cancer target. In pursuit of safe and effective anti-cancer chemotherapy, we preformed three-round structural optimization and developed several potent HDAC6-selective inhibitors. Among these, HDSI-18 exhibited remarkable inhibitory activity (IC₅₀ = 1.6 nM) and exceptional isoform selectivity (over 975-fold) against HDAC6. Further biological evaluations highlighted the promising properties of HDSI-18 in terms of anti-proliferative activity, mitochondrial depolarization, caspase-3 activation, apoptosis induction and druggability (both in vivo and in vitro). This study demonstrated a paradigm for the rational structural optimization of HDAC6 selective inhibitors, which may serve as a beacon for the development of more promiscuous compounds.

项与 Rocilinostat 相关的新闻（医药）

2022-09-28

·BioSpace

Portfolio Highlights: Clinical and Financial Updates of ABM, F5, AceLink, HAYA, Regenacy, and Arthrosi

SHANGHAI, Sept. 28, 2022 /PRNewswire/ -- As the investment division of Viva Biotech, Viva BioInnovator is committed to being a collaborative platform for Innovative Biotech companies from around the world. Over the past 2 months, our portfolio companies progressed greatly. ABM Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ABM-1310 in China On September 16, 2022, ABM Therapeutics, a clinical-stage biopharmaceutical company that is invested and incubated by Viva BioInnovator, announced that the first patient has been successfully dosed with ABM-1310 in a multi-center phase I clinical trial in China. ABM-1310, ABM Therapeutic's proprietary clinical candidate developed as a next-generation BRAF inhibitor, is a highly selective, highly water-soluble, orally administrated, and brain-penetrant small molecule BRAF inhibitor. ABM-1310 phase I trial, conducted in China, is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ABM-1310 in Chinese patients with BRAF V600X mutated advanced solid tumors. F5 Therapeutics awarded First Servier FAST Discovery Award F5 Therapeutics, which invested and incubated by Viva BioInnovator, was recently awarded the first Servier FAST Discovery Award. Winning this award means F5 stood out from 23 applications, indicating the industry's recognition of F5's innovative treatment methods in the field of biomedicine. "Servier FAST Discovery Award" is co-sponsored by Servier and the California Life Sciences Association (CLSA) to support early-stage life science companies using innovative approaches in areas designated by the group: oncology, auto-immune diseases, genetically driven neurodegenerative, and movement disorders. F5 is transforming targeted protein degradation to advance drug discovery by utilizing the cell's normal protein regulation systems to remove disease-causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to "molecular glues" capable of delivering effective medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. AceLink Therapeutics Receives Orphan Drug Designation for its Novel GCS inhibitor AL01211 for the Treatment of Fabry Disease AceLink Therapeutics, Inc. (AceLink), invested and incubated by Viva BioInnovator, is an innovative biopharmaceutical company developing transformative therapies for genetic diseases. On September 7, 2022, they announced that they received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry Disease. AL01211 was selected based on its unique properties to effectively treat peripheral organs that Fabry disease affects by reducing the risk of off-target effects by preventing the crossing of the blood-brain barrier. HAYA Therapeutics won the "TOP 100 Swiss Startup Award 2022" and was successfully selected for the "Soonicorn Club 2022" On Sept. 7th, 2022, the "Top 100 Swiss Startup Award 2022," sponsored by Venturelab, was announced. HAYA Therapeutics, invested and incubated by Viva BioInnovator, was named TOP100 Swiss Startups' 8th Best Startup and came first in the Cardiovascular & Drug Discovery sectors. In addition, HAYA Therapeutics was recently included in the"SoonicornClub 2022", which names the top Swiss technology startups. The awards given demonstrate the industry's recognition of their potential in the field of biomedicine. Regenacy Pharmaceuticals Announces Completion of Enrollment for their Phase 2 Study in Diabetic Peripheral Neuropathy and $9.3 Million in Series B Financing Regenacy Pharmaceuticals Inc, invested and incubated by Viva BioInnovator, is a clinical-stage, biopharmaceutical company developing breakthrough treatments for diabetes and other peripheral neuropathies. On August 24, 2022, they announced completion of enrollment for the company's phase 2 study of ricolinostat, an oral selective deacetylase 6 (HDAC6) inhibitor for painful diabetic peripheral neuropathy (DPN). The company also announced the closing of a $9.3 million Series B financing led by Cobro Ventures. Arthrosi Completes AR882 Renal Impairment Study and its Phase 2b Study Enrollment Arthrosi Therapeutics, Inc., which invested and incubated by Viva BioInnovator, is a clinical-stage biotechnology company focused on the treatment and management of gout. On August 9, 2022, they announced the completion of their renal impairment study that utilizes the lead compound, AR882. AR882 is a potent and selective uricosuric agent which has shown effectiveness in lowering serum urate in patients with normal renal function and in patients with mild to severe renal impairment. On Aug. 23, 2022, Arthrosi announced the completion of enrollment for its global Phase 2b clinical study of AR882 for the treatment of chronic gout. The study, which exceeded the initial target enrollment of 120 patients, is designed to evaluate the safety and efficacy of AR882 in chronic gout patients who meet ACR/EULAR gout classification. About ABM Therapeutics ABM Therapeutics, a clinical-stage biopharmaceutical company with a mission to focus on the small molecule research and development of novel drugs for the treatment of cancer, and on brain cancer and cancer metastases. ABM has been building its broad and robust proprietary pipeline to construct a brain medicine R&D platform through collaboration with CROs. ABM's pipeline includes several programs in various stages of discovery and development, most of which have improved brain permeability to address the unmet needs of treating cancers and metastases in the brain. About F5 Therapeutics F5 is evolving targeted protein degradation to transform the landscape of drug discovery by utilizing the cell's normal protein regulation systems to remove disease causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to "molecular glues" capable of delivering impactful medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration. About AceLink Therapeutics Founded in 2018, AceLink Therapeutics is an innovative biopharma startup focusing on developing safe and effective medicines to address genetic diseases with high unmet needs. The company's initial focus is to develop novel therapeutics for Fabry disease. For more information, please visit . About HAYA Therapeutics HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company's discovery engine focuses on long non-coding RNAs (lncRNAs) within the "dark matter" of the human genome -- key tissue and cell-specific drivers of fibrosis and other disease processes -- to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. About Regenacy Regenacy Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company's selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders. About Arthrosi Therapeutics Arthrosi Therapeutics, Inc. was founded in San Diego, CA, in 2018 with a mission to create a revolutionary treatment option to target uric acid levels and reduce joint damage for people living with gout. With its vast therapeutic and treatment knowledge, Arthrosi has accumulated a comprehensive and robust intellectual property portfolio and impressive Phase I and Phase II data showing industry leading efficacy rates and superior safety pro To learn more about Arthrosi, please visit View original content: SOURCE Viva Biotech Holdings

合作孤儿药小分子药物

2022-08-25

·BioSpace

Regenacy Pharmaceuticals Announces Completion of Enrollment for Phase 2 Study in Diabetic Peripheral Neuropathy & $9.3 Million Series B Financing

WALTHAM, Mass.--(BUSINESS WIRE)-- Regenacy Pharmaceuticals Inc, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced completion of enrollment of the company’s phase 2 study of ricolinostat, an oral selective histone deacetylase 6 (HDAC6) inhibitor, in painful diabetic peripheral neuropathy (DPN). The company also announced the closing of a $9.3 million Series B financing led by Cobro Ventures with participation from Taiwania Capital Management Corporation, 3E Bioventures Capital, Yonjin Venture, and other undisclosed private investors. Painful DPN is characterized by debilitating symptoms that include pain, aberrant sensation, and loss of motor and sensory function. There is an important medical need for new treatments since available therapies do not address the full spectrum of signs and symptoms and offer only limited relief for many patients. Ricolinostat, and other HDAC6 inhibitors, have shown efficacy in animal models of DPN, chemotherapy-induced peripheral neuropathy (CIPN) and Type 2 Charcot Marie Tooth (CMT) disease, and have demonstrated a promising safety and tolerability profile. The ongoing double-blinded placebo-controlled clinical study, which recently completed enrollment, assesses the efficacy of ricolinostat in patients with painful DPN and other neuropathic symptoms. Initial results are expected to be available later this year. Regenacy plans to use the additional financing from this Series B to continue advancing the ricolinostat clinical development program. “Regenacy is committed to exploring ricolinostat’s unique and differentiating potential to address the underlying pathophysiology of small fiber neuropathies,” said David Michelson, M.D., Regenacy’s Chief Medical Officer. “The compelling data we have seen in preclinical studies indicate ricolinostat’s selective inhibition of HDAC6 may provide meaningful relief to patients suffering from painful DPN and other neuropathies, and we look forward to its continued progression in the clinic.” “We are energized by the ongoing support of our investors who share in our mission to address the underlying causes of peripheral neuropathy,” said John Rocha, Regenacy’s Chief Financial Officer. “This Series B positions Regenacy for continued progress as we uncover the potential of ricolinostat to restore peripheral nerve function.” “We at Regenacy believe that ricolinostat shows first-in-class potential to go beyond symptomatic treatment and instill lasting disease-modifying effects for patients with peripheral neuropathies,” said Simon Jones, Ph.D., Regenacy’s President and Chief Executive Officer. “This Series B financing comes at a pivotal stage in our clinical development, as we continue to evaluate ricolinostat in painful diabetic peripheral neuropathy while simultaneously advancing our joint venture Beijing 3E-Regenacy Pharmaceuticals Co., Ltd. to investigate ricolinostat in patients with chemotherapy-induced peripheral neuropathy (CIPN) in China.” Concurrent with the financing, Todd Kaloudis, Managing Director at Cobro Ventures, has joined Regenacy’s Board of Directors. Additionally, Regenacy announced the appointment of William W. Chin, M.D., SVP of Clinical and Translational Science at Frequency Therapeutics, as Executive Chairman of the Board and Michael Huang, Managing Partner at Taiwania Capital, as Vice-Chairman, effective immediately. Mr. Huang has served on Regenacy’s Board since 2020, and Dr. Chin has served since 2018 and is Chairman of Regenacy’s Scientific Advisory Board. About Ricolinostat Ricolinostat, an oral, selective histone deacetylase 6 (HDAC6) inhibitor, has the potential to become the first-in-class treatment that reverses the underlying peripheral neuropathy, thereby relieving pain, numbness, motor function loss, and all other symptoms of the disease. Ricolinostat restores nerve function by inhibiting HDAC6, which reestablishes the transport function of microtubules in the axon of the nerve cell. A functioning microtubule transport system is the key to restoring nerve function because nerves rely on this network to supply the energy and nutrients necessary to maintain the nerve signaling in the ends of the nerves in the skin and muscles of the feet and hands. When this transport is disrupted by a disease like diabetes or neurotoxic drugs used in chemotherapy, nerve cells can malfunction and send random signals (pain, tingling, muscle spasms) or no signal at all (numbness, paralysis). Multiple preclinical animal models have demonstrated that HDAC6 inhibition restores nerve fibers, leading to the reversal of both pain and numbness in peripheral and other neuropathies, such as diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN) and Charcot-Marie-Tooth disease Type 2, an orphan-designated disease. About Regenacy Regenacy Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions. The company’s selective inhibition technology provides superior safety profiles and potential enhanced efficacy compared to non-selective HDAC inhibitors. Regenacy selectively inhibits histone deacetylase 6 (HDAC6) to restore normal intracellular protein and organelle transport in peripheral neuropathies, and also has a portfolio of selective HDACs 1 and 2 inhibitors that have potential to treat major blood diseases such as leukemia, sickle cell disease, β-thalassemia, and cognitive dysfunction in neurological disorders.

First in Class

2022-08-05

·生物谷

Cell Stem Cell: 我国科学家在化学重编程获得巨核细胞及血小板研究领域取得重要突破

运用化学重编程技术实现了人成红细胞向巨核细胞及血小板的命运转换，并利用单细胞转录组和染色质开放性测序技术系统追踪了该过程中的细胞动态变化。血小板是由骨髓等造血组织中巨核细胞产生的具有生物活性的无核细胞，在机体止血、血栓形成、免疫调节、抗感染等生理和病理过程中发挥重要作用。临床上，血小板减少症常见于再生障碍性贫血、特发性血小板减少性紫癜等血液系统疾病。此外，病毒/细菌性感染、创伤、急性放射病、肿瘤放化疗等也易引发血小板减少。血小板输注是临床治疗血小板减少症、防治出血、挽救生命的主要手段之一。然而临床上血小板供应仅有健康志愿者捐献的唯一途径，而血小板贮存时间短且易被污染，遇到战争、重大自然灾害、突发公共卫生事件（如突发传染病）发生时，血小板短缺问题就会更加突出，因此亟需运用新技术解决血小板来源问题。基于干细胞技术、细胞重编程技术获取巨核细胞及血小板的研究一直是国际竞争的前沿与热点领域之一。体外仅通过化学小分子介导的重编程技术制备人巨核细胞（血小板的前体细胞）及血小板的研究成果鲜有报道。近日，军事医学研究院裴雪涛/李艳华团队联合天津大学医学部张健课题组运用化学重编程技术实现了人成红细胞向巨核细胞及血小板的命运转换，并利用单细胞转录组和染色质开放性测序技术系统追踪了该过程中的细胞动态变化。2022年8月4日，干细胞领域顶级期刊《Cell Stem Cell》（《细胞·干细胞》）在线发表了相关研究论文。在细胞重编程的研究中，种子细胞的选择对于能否成功而有效地启动细胞命运转换至关重要。前期研究表明，起始细胞和目的细胞在发育谱系上亲缘关系越近，越容易实现细胞类型转化。成红细胞是存在于骨髓、外周血和脐带血中的一种有核红细胞，成红细胞和巨核细胞在发育过程中来自共同的前体，即巨核-红系共祖细胞，它们之间紧密的谱系联系使成红细胞成为获得巨核细胞理想的候选种子细胞。研究人员通过从多个表观遗传调控和信号通路相关的小分子化合物中筛选出一个含有四个小分子的化合物组合，惊奇地发现该小分子化合物“鸡尾酒”能将人成红细胞高效地重编程为巨核细胞。研究人员进一步确定了两阶段的诱导及巨核细胞特化的体系，最终获得了与天然巨核细胞特性相似的诱导性巨核细胞（induced megakaryocytes, iMKs）。巨核细胞最重要的功能是能产生前血小板及血小板。研究人员首先通过体外实验分析iMKs是否具有生成血小板的能力。在体外特定诱导分化条件下，iMKs能够形成网状的具有多个分支延伸突起的前血小板并释放血小板。更为重要的是，研究人员发现iMKs来源的血小板表现出与天然血小板相似的凝血酶激活响应，并具有粘附、聚集等功能。为了确定iMKs是否具有体内生成功能性血小板的能力，研究人员将iMKs直接通过尾静脉注射到血小板减低症的免疫缺陷小鼠体内，他们在iMKs输注后的第1-3天检测到了人源性血小板，并通过微流控实验证实这些血小板具有参与血栓形成的能力。为了解析四个小分子“鸡尾酒”如何实现成红细胞向巨核细胞的谱系命运转变，研究人员运用单细胞测序技术、染色质开放性测序技术对重编程过程进行了系统追踪和深度剖析。他们发现起始细胞经历了一个红系/巨核共前体细胞的阶段，该阶段的细胞具有红细胞及巨核细胞的双向分化潜能。进一步分析发现，该化合物组合引发了广泛的染色质重塑变化，红系细胞发育关键性基因的染色质开放程度逐渐降低，造血及巨核发生相关的重要转录因子基因位点的染色质开放程度逐渐升高，从而逐渐启动了巨核细胞发育程序。值得注意的是，他们发现iMKs可以分为两个亚群，其中一个亚群为血小板生成偏向性强的巨核细胞，在iMKs总群体中的比例大于70%。另一个亚群是免疫偏向性的巨核系细胞，可能在免疫调节、炎症调节过程中发挥作用。四分子的重编程体系更有利于产生血小板生成偏向性强的巨核细胞。综上所述，该研究团队独辟蹊径，仅运用小分子化合物成功实现成红细胞向功能性巨核细胞及血小板的命运转变，为体外大规模人工制备巨核细胞和血小板开辟了新的路径。该化学重编程技术具有安全可控、高效便捷等优势，通过该技术获得的功能性巨核细胞及血小板有望为临床血小板短缺等问题的解决开辟全新的途径，在血液系统疾病、急性放射病、战创伤、病毒或细菌性传染病等多种疾病引发的血小板减少症、出血的防治等方面展现出潜在的临床应用价值。军事医学研究院裴雪涛研究员和李艳华研究员为该论文的共同通讯作者。军事医学研究院覃金华副研究员、天津大学医学部张健副教授以及军事医学研究院博士研究生姜佳楠是论文的并列第一作者。该研究得到国家重点研发计划和国家自然科学基金的支持和资助。

小分子药物

100 项与 Rocilinostat 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12376

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
糖尿病周围神经性疼痛	临床2期	美国	Regenacy Pharmaceuticals LLC	2020-12-07
霍奇金淋巴瘤	临床2期	美国	Acetylon Pharmaceuticals, Inc.	2014-04-02
套细胞淋巴瘤	临床2期	美国	Acetylon Pharmaceuticals, Inc.	2014-04-02
多发性骨髓瘤	临床2期	美国	Acetylon Pharmaceuticals, Inc.	2014-04-02
难治性非霍奇金淋巴瘤	临床2期	美国	Acetylon Pharmaceuticals, Inc.	2014-04-02
难治性多发性骨髓瘤	临床2期	美国	Celgene Corp.	2014-03-01
复发性多发性骨髓瘤	临床2期	美国	Celgene Corp.	2014-03-01
乳腺癌	临床1期	中国	北京本草瑞生医药科技香港有限公司	2022-11-17
神经炎	临床1期	中国	北京本草瑞生医药科技香港有限公司	2022-11-17
卵巢癌	临床1期	美国	Celgene Corp.	2016-06-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01997840 (CTgov)	临床1/2期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	103	pomalidomide+dexamethasone+ACY-1215 (Phase 1b - ACY-1215)	淵積願餘願鑰壓選蓋醖 = 蓋構顧鹹繭構鹽蓋齋憲觸窪願窪夢鑰醖鏇壓鏇 (鏇鏇範餘鹽廠夢築夢鏇, 遞選網夢選齋衊蓋淵壓 ~ 積艱範觸鑰築齋構襯壓)	-	2025-03-04
NCT01997840 (CTgov)	临床1/2期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	103	ACY-1215 (Phase 2 - ACY-1215 Dose Level 1)	願衊鏇鏇夢壓鏇醖簾艱 = 簾選壓鑰鹹艱壓艱壓獵糧繭壓網顧鬱鑰觸鹹夢 (廠觸製選繭襯鏇鹽憲窪, 鑰範選顧觸廠醖願繭淵 ~ 鏇願窪簾蓋築淵廠鹽網) 更多	-	2025-03-04
NCT03176472 (CTgov)	临床2期	糖尿病周围神经性疼痛	282	ricolinostat (Ricolinostat)	遞願製鏇獵網衊繭簾網(糧獵鬱衊遞願夢糧鹹襯) = 襯積繭築艱憲蓋鹹糧繭齋簾獵遞齋夢鏇鑰憲獵 (襯繭鹹繭鹹夢廠觸壓鹹, 1.4) 更多	-	2023-09-21
NCT03176472 (CTgov)	临床2期	糖尿病周围神经性疼痛	282	Placebo (Placebo)	遞願製鏇獵網衊繭簾網(糧獵鬱衊遞願夢糧鹹襯) = 鏇夢網簾糧蓋艱繭觸鹹齋簾獵遞齋夢鏇鑰憲獵 (襯繭鹹繭鹹夢廠觸壓鹹, 1.4) 更多	-	2023-09-21
AACR2020	临床1/2期	转移性乳腺癌	16	Ricolinostat 240 mg qd + nab-paclitaxel	夢鏇鏇廠觸遞鹹鹽艱顧(網簾願鬱選壓鏇膚鏇獵) = 襯憲艱顧窪齋齋願鹹膚夢鏇淵範選齋鑰齋蓋艱 (廠糧襯鑰繭淵願蓋製製, 4.45 ~ 11.0)	积极	2020-08-15
P1-19-27 (SABCS2020)	临床1期	转移性乳腺癌 HDAC6 score	17	ACY-1215 240 mg qd + nab-paclitaxel 100 mg/m2	遞選衊積獵鬱顧壓鑰壓(觸膚鑰餘襯憲製淵製鬱) = neutropenia (n=1), peripheral neuropathy (n=1), and 1 grade IV neutropenia 艱窪築衊簾網夢獵觸壓 (艱簾齋獵艱蓋鏇壓觸繭 ) 更多	积极	2020-02-15
NCT02661815 (CTgov)	临床1期	原发性腹膜癌 \| 卵巢癌 \| 复发性铂耐药性输卵管癌	6	Paclitaxel+Ricolinostat (Phase 1 Escalation Cohort)	衊鑰鏇觸壓製鏇糧積艱 = 積選遞積艱範顧網鬱餘鬱遞鬱繭襯夢築醖廠蓋 (遞廠膚獵願願壓選範積, 艱鑰繭築築窪範遞製繭 ~ 鹹餘網簾襯選鑰鬱鬱觸) 更多	-	2019-11-08
NCT02661815 (CTgov)	临床1期	原发性腹膜癌 \| 卵巢癌 \| 复发性铂耐药性输卵管癌	6	Paclitaxel+Ricolinostat (Phase 1 Expansion Cohort A)	鏇蓋淵壓願襯選鬱壓鏇(窪築顧簾獵窪鏇壓顧觸) = 範餘窪築築簾鑰築衊獵製壓獵夢築糧選餘遞繭 (築夢壓顧鬱糧製築製願, 觸淵鹹鏇壓膚築繭壓壓 ~ 觸築餘齋顧艱糧廠膚顧) 更多	-	2019-11-08
NCT02661815 (Pubmed) 人工标引	临床1期	复发性卵巢癌 \| 铂类耐药性原发性腹膜癌 \| 输卵管癌二线	6	paclitaxel+ricolinostat	選齋廠壓艱夢顧窪製構(積蓋鑰糧獵淵積鏇鏇鬱) = 簾淵獵襯範繭鏇窪鹽簾鏇鏇構鑰獵顧鏇鹹膚蓋 (膚網遞窪獵鏇齋願選願 ) 更多	积极	2019-08-10
NCT02632071 (ASCO 12018 \| ASCO 22018) 人工标引	临床1期	转移性乳腺癌	17	ACY-1215+nab-paclitaxel	壓夢網廠廠網窪餘壓鹹(願鏇餘顧網夢築積艱餘) = none 鹽襯選糧築範願築夢選 (艱淵壓製壓襯餘獵壓積 ) 更多	积极	2018-06-02
NCT01583283 (Pubmed \| Lancet Oncol) 人工标引	临床1期	多发性骨髓瘤	38	lenalidomide+dexamethasone+ricolinostat	淵齋簾積憲淵膚糧觸鏇(鹹積觸膚憲醖觸膚獵衊) = icolinostat（160 mg once daily on days 1-21 of a 28 day cycle）+ lenalidomide（25 mg）+dexamethasone（40 mg）壓簾願膚鹹壓願艱窪蓋 (襯築簾膚鏇鏇鑰鬱蓋簾 ) 更多	积极	2016-11-01